News for Cue Biopharma, Inc. (CUE)

Cue Biopharma, Inc. (NASDAQ:CUE) Business Update Call April 15, 2025 4:30 PM ETCompany ParticipantsEric Ribner - LifeSci AdvisorsDan Passeri - Chief...

\nPublic Offering: Announced a $20 million public offering, including 13,530,780 shares of common stock and warrants for an additional 3,382,695 shares.Warrant D

Cue Biopharma (CUE) stock in focus as the company collaborates with Boehringer Ingelheim to develop CUE-501, for autoimmune and inflammatory diseases. Read more here.

**media[595135]**

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeut

Cue Biopharma (CUE) announces a public offering projected to raise approximately $20 million in gross proceeds. The offering is set at $0.79 per common

Cue Biopharma, trading under the ticker CUE, has initiated an underwritten public offering comprising its common stock and accompanying warrants. The entire off

Partnership bolsters Boehringer's autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need.The agreement focuses

**media[594950]**

Cue Biopharma (CUE) delivered earnings and revenue surprises of 18.75% and 5.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[582035]**

Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing conti

Transaction Overview On March 19, 2025, Bleichroeder LP (Trades, Portfolio), an investment firm, made a significant addition to its holdings in Cue Biopharma In

On December 31, 2024, Slate Path Capital LP (Trades, Portfolio) executed a significant transaction involving Cue Biopharma Inc, a clinical-stage biopharmaceutic

BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. ( CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeuti

BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. ( CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biolo

Cue Biopharma (CUE) delivered earnings and revenue surprises of 15% and 205.22%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[466687]**

**media[460629]**